Skip to main content

Merck Value Stock - Dividend - Research Selection

Merck & Co Inc

ISIN: US58933Y1055, WKN: A0YD8Q

Market price date: 24.01.2022
Market price: 78,83 USD

Merck & Co Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 27-02-2021
Cash flow
Net operating cash flow
Capital Expenditures -4.684.000.000
Free cash flow 5.568.999.936
Balance sheet
Total Equity 25.317.000.000
Liabilities & Shareholders equity 91.588.000.000
Income statement
Net income
Eps (diluted) 2,780
Diluted shares outstanding 2.541.000.000
Net sales/revenue 47.994.000.000

Fundamental ratios calculated on: 24-01-2022

Key figures 24-01-2022
Cash flow
P/C 19,82
P/FC 35,97
Balance sheet
Income statement
Div. Yield3,10%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization203.229.184.000,00 USD
CountryUnited States
IndicesDow Jones Industrial Average,S&P 500,MSCI World Index
Raw Data SourceUS GAAP in Millionen USD
Stock Split2021-06-03,1048.000000/1000.000000; 1999-02-17,2.0000/1.0000; 1997-06-04,1.000000/1.000000; 1995-06-12,1.000000/1.000000; 1992-05-26,3.0000/1.0000; 1988-05-26,3.0000/1.0000; 1986-05-27,2.0000/1.0000; 1972-06-01,2.0000/1.0000

Description of the company

Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc's Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


S&P 500 Follows Nasdaq Into Correction; Fear Index Up

The January dive for stocks steepened. The Dow Jones Industrial Average (DJIA) dropped 1,000 points as the CBOE Volatility Index (VIX) spiked.

Westbourne Investment Advisors, Inc. Buys Philip Morris International Inc, PepsiCo Inc, Splunk ...

Investment company Westbourne Investment Advisors, Inc. (Current Portfolio) buys Philip Morris International Inc, PepsiCo Inc, Splunk Inc, McDonald's Corp, Altria Group Inc, sells ISHARES TRUST, Vanguard Intermediate-Term Corporate Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Westbourne Investment Advisors, Inc..

Advanced Asset Management Advisors Inc Buys Visa Inc, Cisco Systems Inc, Verizon Communications ...

Investment company Advanced Asset Management Advisors Inc (Current Portfolio) buys Visa Inc, Cisco Systems Inc, Verizon Communications Inc, Merck Inc, Intuit Inc, sells ISHARES TRUST, Vanguard Growth ETF, Oracle Corp, Edwards Lifesciences Corp, Masco Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Advanced Asset Management Advisors Inc.

U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments

The U.S. health regulator on Monday revised the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron variant.

FDA has questions about Merck's experimental chronic cough drug

The chronic cough drug was approved in Japan, where it will be marketed under the brand name Lyfnua.

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

EU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck

The European Union's drug regulator is set to decide whether to approve Pfizer's COVID-19 pill at the end of this month, before doing a final review of Merck's similar but less effective drug in February, a source with knowledge of the matter said.

Egypt approves Merck COVID pill, says to be produced locally

Egypt approved Merck & Co's COVID-19 pill Molnupiravir for emergency use, the country's drug authority said on Monday, adding that the pill would be locally produced.

Merck & Co (MRK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

The following slide deck was published by Merck & Co., Inc.

Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition

Netflix tumbled for a second day on Monday after the company's weaker-than-expected subscriber forecast.